These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15667232)

  • 61. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.
    Watkins JB; Minshall ME; Sullivan SD
    J Manag Care Pharm; 2006; 12(9):726-35. PubMed ID: 17249905
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
    Scheinfeld N
    J Dermatolog Treat; 2007; 18(4):197-208. PubMed ID: 17671880
    [TBL] [Abstract][Full Text] [Related]  

  • 63. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
    Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
    J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre.
    Warren RB; Brown BC; Lavery D; Ashcroft DM; Griffiths CE
    Br J Dermatol; 2009 Jan; 160(1):162-9. PubMed ID: 18808412
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.
    Rustin MH
    Br J Dermatol; 2012 Nov; 167 Suppl 3():3-11. PubMed ID: 23082810
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability?
    Shear NH
    Drug Saf; 2006; 29(1):49-66. PubMed ID: 16454534
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
    Doan QV; Chiou CF; Dubois RW
    J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.
    Mease PJ; Armstrong AW
    Drugs; 2014 Mar; 74(4):423-41. PubMed ID: 24566842
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
    Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Ighani A; Georgakopoulos JR; Yeung J
    G Ital Dermatol Venereol; 2020 Aug; 155(4):400-410. PubMed ID: 32348084
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis.
    Kivelevitch D; Mansouri B; Menter A
    Biologics; 2014; 8():169-82. PubMed ID: 24790410
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.
    Napolitano M; Balato N; Caso F; Costa L; Megna M; Cirillo T; Balato A; Scarpa R
    Clin Exp Rheumatol; 2017; 35(1):137-140. PubMed ID: 27749221
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Biologic therapies for psoriasis. A systematic review.
    Boehncke WH; Prinz J; Gottlieb AB
    J Rheumatol; 2006 Jul; 33(7):1447-51. PubMed ID: 16724367
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.
    Kitamura G; Mehr N; Anderson N; Sirichotiratana M
    Dermatol Online J; 2009 Feb; 15(2):11. PubMed ID: 19336028
    [TBL] [Abstract][Full Text] [Related]  

  • 76. New biologic therapies for psoriatic disease.
    Bohjanen KA; Prawer SE
    Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.
    Armstrong AW; Brezinski EA; Follansbee MR; Armstrong EJ
    Curr Pharm Des; 2014; 20(4):500-12. PubMed ID: 23565631
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.
    Armstrong AW; Robertson AD; Wu J; Schupp C; Lebwohl MG
    JAMA Dermatol; 2013 Oct; 149(10):1180-5. PubMed ID: 23945732
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.